Rethinking our strategies to develop disease-modifying therapies for Parkinson's: Time for combination therapies?
publications). The lack of progress towards slowing the disease is further highlighted by the recent disappointing results from high profile, Phase 2/3 clinical trials for DMTs. In this commentary, we would like to suggest an alternative strategy for identifying DMTs. Specifically, we propose the evaluation of rationally designed combination therapies that target multiple PD etiological factors.
Authors
- Joy Duffen (ORCID: https://orcid.org/0000-0002-0149-6656)
- Radi Haloub (ORCID: https://orcid.org/0000-0002-7645-3677)
- Anthony H.V. Schapira (ORCID: https://orcid.org/0000-0002-3018-3966)
- Simon Stott (ORCID: https://orcid.org/0000-0002-5741-4664)
- Helen Matthews
Institutions
- Parkinson's UK (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of Parkinson s Disease
- Published
- 2026-04-21
- DOI
- https://doi.org/10.1177/1877718x261434686
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Innovate UK